On the one hand, Th17 cells enhance anti-tumor immune responses by stimulating immune cells in the TME, becoming the Th1 phenotype, producing abundant IFN-γ or inducing effector CD8+ T cells. The gene discussed is CD8A; the disease is neoplasm.